title: Efficacy of induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin.
abstract: From August 1986 to July 1989, 98 patients receiving primary cadaveric kidney transplants received either RATS (n = 50) or MALG (n = 48) during the induction phase of a quadruple immunosuppressive protocol. Patient groups were well matched. The duration of RATS and MALG treatment and the time of CyA induction were equivalent. Serum creatinine and rejection episodes up to 1 year were not statistically different. Hematologic side effects resulted in dose reduction of MALG in 42% of patients without adverse rejection results. In the RATS group, no dosage reductions were required. One-year patient survivals (96% to 100%), and 1-year graft survival (82% to 85%) were not significantly different in the 2 groups. Infectious complications were 30% higher in the MALG group and a significant factor in 2 deaths. Monitoring of lymphocyte subsets revealed insignificant differences in the percent of decrease of each cell population between MALG and RATS groups during induction.
authors.affiliation: Department of Surgery, University of Cincinnati Medical Center, Ohio 45267-0558.
authors.forename: R A
authors.initials: RA
authors.lastname: Fisher
authors.forename: J I
authors.initials: JI
authors.lastname: Tchervenkov
authors.forename: T J
authors.initials: TJ
authors.lastname: Schroeder
authors.forename: J W
authors.initials: JW
authors.lastname: Alexander
authors.forename: R
authors.initials: R
authors.lastname: Munda
authors.forename: I
authors.initials: I
authors.lastname: Penn
authors.forename: M
authors.initials: M
authors.lastname: Carey
authors.forename: M R
authors.initials: MR
authors.lastname: First
mesh_terms: D000328:Adult; D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D000961:Antilymphocyte Serum / Q000592:standards*; D002102:Cadaver; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology / Q000379:methods*; D008297:Male; D009894:Opportunistic Infections / Q000150:complications; D011817:Rabbits; D016019:Survival Analysis; D016176:T-Lymphocyte Subsets / Q000276:immunology
chemical_list: D015703:Antigens, CD; D000961:Antilymphocyte Serum